J&J Medical Connect
RYBREVANT FASPRO™

(amivantamab and hyaluronidase-lpuj)

J&J Medical Connect

Connect with us

Connect with us

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj)

Medical Information

RYBREVANT FASPRO - Density

Last Updated: 12/17/2025

SUMMARY  

  • Please refer to product labeling for storage and stability information.
  • The company cannot recommend any practices, procedures, or storage conditions that deviate from product labeling and are not approved by the regulatory agencies.
  • The density of RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) injection for subcutaneous use (amivantamab 160 mg/mL) is 1.071 g/mL (at 20°C).1 

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 09 December 2025.

References

Show
1 Data on File. Technical Document Technology Transfer Report for Amivantamab (JNJ-61186372, CNTO 4424) Subcutaneous (SC), 1600, 2240, 2400 and 3520 mg/vial Final Vialed Product (FVP) Fill-Finish Manufacturing Process at Lyophilization Production Facility (LPF) at Janssen Supply Chain (JSC), Schaffhausen, Switzerland. Janssen Research & Development, LLC. TV-TEC-310321 v2.0; 2025.